{"name":"Carina Mari Aparici","slug":"carina-mari-aparici","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBVY09uazB2U2lXdkhILXNwMFJIQ2FRSm9aRlB2ZXNBckhGdk9Ob0tJUy1uUW5WVHkxV3J0Y1VGcThpRTNvVkdUMzMwRHhULWZveDlHeEtPSmcyOXdwY2tDZmlDUVF2bTQ?oc=5","date":"2022-08-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Evaluation of Interim Dotatate-PET after Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET) - jnm.snmjournals.org","headline":"Evaluation of Interim Dotatate-PET after Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5oTDdwVU8ycUNfY05Ia3VmeHVhamRvMjd0dkxWSjZuTDlNNGhXWUNMRFlNT191Z3YwOW4tQ2htSmV4ckxsdThkaktTS2IzNjNHOGtxLVVzZw?oc=5","date":"2019-07-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms - jnm.snmjournals.org","headline":"Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}